Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 5, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-DASATINIB (DIN 02478323) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02478323 | approvedsource: Marketed | health-canada-dpd |
| May 5, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-DASATINIB (DIN 02478315) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02478315 | approvedsource: Marketed | health-canada-dpd |
| May 5, 2021 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-DASATINIB (DIN 02478307) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database… | DIN02478307 | approvedsource: Marketed | health-canada-dpd |
| May 5, 2021 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-05-05 (see label) | SUPPLBLA125514 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 27, 2021 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP IMATINIB (DIN 02495074) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02495074 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 31, 2021 | Isatuximab | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-31 (see label) | SUPPLBLA761113 | approved | openfda |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| withdrawnsource: Dormantsince Jul 31, 2025 |
| health-canada-dpd |
| Apr 27, 2021 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP IMATINIB (DIN 02495066) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02495066 | withdrawnsource: Dormantsince Jul 31, 2025 | health-canada-dpd |
| Apr 26, 2021 | Abiraterone | EMA EU | Castration-Resistant Prostate Carcinoma | Abiraterone Accord is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone… | centralisedEMEA/H/C/005408 | approved | ema |
| Apr 23, 2021 | Loncastuximab Tesirine | FDA US | High Grade B-Cell Lymphoma | ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of… | ORIGBLA761196 | approved | openfda |
| Apr 22, 2021 | Dostarlimab | FDA US | Tumor-agnostic | as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an… | ORIGBLA761174 | approved | openfda |
| Apr 22, 2021 | Dostarlimab | FDA US | Malignant Endometrial Neoplasm | Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult… | ORIGBLA761174 | approved | openfda |
| Apr 21, 2021 | Bevacizumab | EMA EU | cancer not stated in this record | Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of… | centralisedEMEA/H/C/005327 | approved | ema |
| Apr 21, 2021 | Dostarlimab | EMA EU | Malignant Endometrial Neoplasm | Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced… | centralisedEMEA/H/C/005204 | approved | ema |
| Apr 21, 2021 | Rituximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RIABNI (DIN 02513447) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see… | DIN02513447 | withdrawnsource: Cancelled Post Marketsince Oct 10, 2024 | health-canada-dpd |
| Apr 16, 2021 | Nivolumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-04-16 (see label) | SUPPLBLA125554 | approved | openfda |
| Apr 13, 2021 | Sacituzumab Govitecan | FDA US | cancer not stated in this record | Efficacy supplement 2021-04-13 (see label) | SUPPLBLA761115 | approved | openfda |
| Apr 13, 2021 | Atezolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-04-13 (see label) | SUPPLBLA761034 | approved | openfda |
| Apr 12, 2021 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-BORTEZOMIB (DIN 02499061) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product… | DIN02499061 | approvedsource: Marketed | health-canada-dpd |
| Apr 9, 2021 | Pertuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHESGO (DIN 02512920) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the Drug Product… | DIN02512920 | approvedsource: Marketed | health-canada-dpd |
| Apr 9, 2021 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHESGO (DIN 02512920) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the Drug Product… | DIN02512920 | approvedsource: Marketed | health-canada-dpd |
| Apr 8, 2021 | Pertuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHESGO (DIN 02512912) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the Drug Product… | DIN02512912 | approvedsource: Marketed | health-canada-dpd |
| Apr 8, 2021 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PHESGO (DIN 02512912) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the Drug Product… | DIN02512912 | approvedsource: Marketed | health-canada-dpd |
| Apr 7, 2021 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMATINIB (DIN 02504618) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see… | DIN02504618 | approvedsource: Marketed | health-canada-dpd |
| Apr 7, 2021 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMATINIB (DIN 02504596) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see… | DIN02504596 | approvedsource: Marketed | health-canada-dpd |
| Apr 7, 2021 | Sacituzumab Govitecan | FDA US | cancer not stated in this record | Efficacy supplement 2021-04-07 (see label) | SUPPLBLA761115 | approved | openfda |
| Apr 7, 2021 | Sacituzumab Govitecan | FDA US | cancer not stated in this record | Efficacy supplement 2021-04-07 (see label) | SUPPLBLA761115 | approved | openfda |
| Apr 6, 2021 | Cetuximab | FDA US | cancer not stated in this record | Efficacy supplement 2021-04-06 (see label) | SUPPLBLA125084 | approved | openfda |
| Apr 6, 2021 | Cetuximab | FDA US | cancer not stated in this record | Efficacy supplement 2021-04-06 (see label) | SUPPLBLA125084 | approved | openfda |
| Mar 30, 2021 | Zanubrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BRUKINSA (DIN 02512963) under ATC L01EL03 ZANUBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02512963 | approvedsource: Marketed | health-canada-dpd |
| Mar 29, 2021 | Methotrexate | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-29 (see label) | SUPPLNDA011719 | approved | openfda |
| Mar 26, 2021 | Bevacizumab | EMA EU | cancer not stated in this record | Oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of… | centralisedEMEA/H/C/005556 | approved | ema |
| Mar 26, 2021 | Thiotepa | EMA EU | cancer not stated in this record | Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products: with or without total body irradiation (TBI), as… | centralisedEMEA/H/C/005434 | approved | ema |
| Mar 26, 2021 | Bevacizumab | EMA EU | cancer not stated in this record | Alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of… | centralisedEMEA/H/C/005286 | approved | ema |
| Mar 26, 2021 | Pemigatinib | EMA EU | Cholangiocarcinoma | Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast… | centralisedEMEA/H/C/005266 | approved | ema |
| Mar 26, 2021 | Selinexor | EMA EU | Multiple Myeloma | NEXPOVIO is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have… | centralisedEMEA/H/C/005127 | approved | ema |
| Mar 26, 2021 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-ABIRATERONE (DIN 02477114) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02477114 | approvedsource: Marketed | health-canada-dpd |
| Mar 25, 2021 | Larotrectinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-25 (see label) | SUPPLNDA211710 | approved | openfda |
| Mar 25, 2021 | Larotrectinib | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-25 (see label) | SUPPLNDA210861 | approved | openfda |
| Mar 24, 2021 | Decitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as DEMYLOCAN (DIN 02484811) under ATC L01BC08 DECITABINE. Indications are not published in the Drug Product Database —… | DIN02484811 | approvedsource: Marketed | health-canada-dpd |
| Mar 22, 2021 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-22 (see label) | SUPPLBLA125514 | approved | openfda |
| Mar 19, 2021 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE (DIN 02504472) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02504472 | approvedsource: Marketed | health-canada-dpd |
| Mar 16, 2021 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-16 (see label) | SUPPLBLA125514 | approved | openfda |
| Mar 16, 2021 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-16 (see label) | SUPPLBLA125514 | approved | openfda |
| Mar 12, 2021 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02498111) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02498111 | withdrawnsource: Cancelled Post Marketsince Sep 25, 2025 | health-canada-dpd |
| Mar 11, 2021 | Blinatumomab | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-11 (see label) | SUPPLBLA125557 | approved | openfda |
| Mar 11, 2021 | Blinatumomab | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-11 (see label) | SUPPLBLA125557 | approved | openfda |
| Mar 11, 2021 | Olaparib | FDA US | cancer not stated in this record | Efficacy supplement 2021-03-11 (see label) | SUPPLNDA208558 | approved | openfda |
| Mar 10, 2021 | Tivozanib | FDA US | Renal Cell Carcinoma | FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or… | ORIGNDA212904 | approved | openfda |
| Mar 10, 2021 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONUREG (DIN 02510200) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug Product Database — see… | DIN02510200 | approvedsource: Marketed | health-canada-dpd |
| Mar 10, 2021 | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONUREG (DIN 02510197) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug Product Database — see… | DIN02510197 | approvedsource: Marketed | health-canada-dpd |